Collegium Pharmaceutical, Inc. (COLL)

35,63 +0,15 (+0,42%) A partir del 10:54AM EDT. Mercado abierto.

Collegium Pharmaceutical, Inc.

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
United States
781 713 3699
https://www.collegiumpharma.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 197

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.	Co-Founder & Independent Chairman	110k	N/A	1964
Mr. Joseph J. Ciaffoni	President, CEO & Director	1,45M	770,46k	1971
Ms. Colleen Tupper	Executive VP & CFO	782,64k	N/A	1976
Ms. Shirley R. Kuhlmann	Executive VP, General Counsel, Chief Administrative Officer & Secretary	788,45k	252,97k	1984
Mr. Scott Dreyer	Executive VP & Chief Commercial Officer	693,54k	N/A	1972
Dr. Thomas B. Smith FAAFP, M.D.	Executive VP & Chief Medical Officer	693,27k	N/A	1961
Dr. Christopher Shayne James M.D.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Bart J. Dunn	Executive Vice President of Strategy & Corporate Development	N/A	N/A	N/A
Mr. Scott Sudduth	Head of Technical Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Collegium Pharmaceutical, Inc., a día 1 de abril de 2024, es 3. Las puntuaciones base son Auditoría: 9; Tablero: 4; Derechos de los accionistas: 2; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.